The impact of metformin use on the outcomes of relapse-remitting multiple sclerosis patients receiving interferon beta 1a: an exploratory prospective phase II open-label randomized controlled trial

ConclusionAdding metformin to IFN β-1a demonstrated a potential effect on an oxidative stress marker (MDA). However, there is no statistically significant effect on immunological, MRI and clinical outcomes. We recommend larger scale studies to confirm or negate these findings.Trial registrationClinicalTrials.gov number: NCT05298670, 28/3/2022.
Source: Journal of Neurology - Category: Neurology Source Type: research